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Abstract
Statin therapy reduces the risk of coronary heart disease (CHD), however, the person-to-person variability in response to
statin therapy is not well understood. We have investigated the effect of genetic variation on the reduction of CHD events
by pravastatin. First, we conducted a genome-wide association study of 682 CHD cases from the Cholesterol and Recurrent
Events (CARE) trial and 383 CHD cases from the West of Scotland Coronary Prevention Study (WOSCOPS), two randomized,
placebo-controlled studies of pravastatin. In a combined case-only analysis, 79 single nucleotide polymorphisms (SNPs)
were associated with differential CHD event reduction by pravastatin according to genotype (P,0.0001), and these SNPs
were analyzed in a second stage that included cases as well as non-cases from CARE and WOSCOPS and patients from the
PROspective Study of Pravastatin in the Elderly at Risk/PHArmacogenomic study of Statins in the Elderly at risk for
cardiovascular disease (PROSPER/PHASE), a randomized placebo controlled study of pravastatin in the elderly. We found
that one of these SNPs (rs13279522) was associated with differential CHD event reduction by pravastatin therapy in all 3
studies: P = 0.002 in CARE, P = 0.01 in WOSCOPS, P = 0.002 in PROSPER/PHASE. In a combined analysis of CARE, WOSCOPS,
and PROSPER/PHASE, the hazard ratio for CHD when comparing pravastatin with placebo decreased by a factor of 0.63 (95%
CI: 0.52 to 0.75) for each extra copy of the minor allele (P = 4.861027). This SNP is located in DnaJ homolog subfamily C
member 5B (DNAJC5B) and merits investigation in additional randomized studies of pravastatin and other statins.
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Introduction
Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMGCR), are widely prescribed to reduce low-density
lipoprotein cholesterol (LDL-C) levels and cardiovascular events.
In an analysis of 14 randomized clinical trials, statin therapy was
associated with about 20% reduction of major cardiovascular
events for each mmol/L (38.7 mg/dL) reduction of LDL-C [1].
Although statins are the most prescribed class of drugs and therapy
is generally associated with LDL cholesterol lowering of 22–34%,
individual variability in response to statin therapy has been noted.
Recent research provides evidence that genetic variation contrib-
utes to this variable drug response [2,3].
Multiple studies investigated whether genetic variants are
associated with differential LDL-C reduction by statin therapy
[4]. Evidence from several studies [5–7] suggests that the e3 allele
of APOE is associated with differential LDL-C lowering by statin
therapy. Additionally, variants of the HMGCR gene have been
also been shown to be associated with differential LDL-C
reduction by statin treatment [6,8,9]. Several studies have
reported an association between a KIF6 variant (rs20455) and
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differential event reduction by pravastatin [10,11] or intensive
atorvastatin therapy [12], however, others found no association
between rs20455 and differential event reduction from simvastatin
[13] or rosuvastatin therapy [14].
To investigate the effect of genetic variation on the reduction of
CHD events by pravastatin we conducted a genome wide
association study (GWAS) in two large randomized controlled
trials that used the same dose of pravastatin: Cholesterol and
Recurrent Events (CARE) trial, and the West of Scotland
Coronary Prevention Study (WOSCOPS) trial and replicated
our findings in a third randomized control trial of pravastatin:
PROspective Study of Pravastatin in the Elderly at Risk/
PHArmacogenomic study of Statins in the Elderly at risk for
cardiovascular disease (PROSPER/PHASE).
Results
A summary of the baseline characteristics of the patients
included in the genetic analyses of CARE, WOSCOPS, and
PROSPER is provided in Table 1. The first stage of this
investigation included patients drawn from the CARE and
WOSCOPS studies who had had an on-study CHD event (see
strategy outline in Figure 1).
Using a case-only analysis of CARE and WOSCOPS we
determined the Synergy Index, an estimate of the interaction
between pravastatin therapy and genotype for each SNP [15]. The
P values for the combined Synergy Index from the CARE and
WOSCOPS studies were calculated and plotted according to
chromosomal position (Figure 2). Loci that included SNPs with
low combined P values (,1025) were found around QTRRTD1
and KIAA1407 on chromosome 3, near LINC00474 on chromo-
some 9, and near FAM9C on chromosome X (Table 2). Overall we
observed 79 SNPs that were nominally (P,1024) associated with
differential event reduction by pravastatin therapy (Table 2).
These 79 SNPs clustered in 45 loci, where a locus is defined by
associated SNPs that were within 100 kb of each other. The 45
loci were all .300 kb apart or on different chromosomes. None of
these SNPs was in or near a gene that had been previously
reported to be associated with CHD, involved in cholesterol
metabolism, or involved in pravastatin metabolism. Furthermore,
none of these SNPs was associated with baseline LDL-C levels
among cases (P.0.05 in a combined analysis of CARE and
WOSCOPS prior to adjustment for testing 45 loci), or with change
in LDL-C levels in the pravastatin group of CARE (P.0.05, prior
to adjustment for testing 45 loci).
In the second stage of this investigation, we analyzed 74 of these
79 SNPs in PROSPER/PHASE (genotypes were not available in
PROSPER/PHASE for the remaining 5 SNPs). We have also
determined the genotypes for the remaining patients from CARE
and WOSCOPS (with or without CHD events) for most of these
74 SNPs and conducted an analysis of these 74 SNPs in the
combined CARE, WOSCOPS, and PROSPER/PHASE studies
(Table 3). We found that one SNP (rs13279522) was associated
with differential event reduction in all three studies (combined P
for interaction between CHD events and pravastatin thera-
py= 4.861027). The minor allele (C) of the rs13279522 SNP
had a frequency of 16% among 2775 self-described Caucasian of
the CARE study and the genotype distribution of this SNPs did
not deviate from Hardy-Weinberg equilibrium expectations
(P = 0.3). The frequency of the C allele was 61% among 76 self-
described African Americans in CARE, 23% among 83 self-
described Hispanics and 19% among 31 self-described Asians or
Pacific islanders. We estimated the risk reduction by pravastatin in
each genotype group in each study and in a combined analysis of
all three studies (Figure 3). The risk reduction by pravastatin
among minor homozygotes was 70% (95%CI 5% to 91%,
P= 0.04) among heterozygotes was 45% (95%CI 33% to 54%,
P= 2.9610210) and among major homozygotes was 13% (95%CI
2% to 24%, P=0.02). This SNP was not associated with baseline
LDL-C levels among cases and non-cases in CARE (P.0.7) or in
PROSPER/PHASE (P.0.18). Neither was it associated with
Table 1. Baseline characteristics of study participants.
CARE WOSCOPS PROSPER/PHASE
Events
(n =711)
No Events
(n =2398)
Events
(n=522)
No Events
(n =4909)
Events
(n=590)
No Events
(n =4654)
Men, n (%) 618 (87) 2065 (86) 522 (100) 4909 (100) 356 (60) 2168 (47)
Age, years 58.369 58.69 56.365 54.666 75.763 75.363
Body mass index, kg/m2 27.965 27.564 26.063 25.963 27.064 26.864
Current Smokers, n (%) 140 (20) 372 (16) 436 (84) 3815 (78) 152 (26) 1240 (27)
History of diabetes, n (%) 136 (19) 290 (12) 11 (2) 56 (1) 83 (14) 461 (10)
History of hypertension, n (%) 335 (47) 993 (41) 118 (23) 730 (15) 361 (61) 2896 (62)
LDL cholesterol, mg/dL 140.0615 138.6615 194.0618 192.2617 143.1627 146.9631
HDL cholesterol, mg/dL 38.268 38.869 41.569 44.369 46.4612 50.3616
Total cholesterol, mg/dL 209.6617 208.617 273.6624 272.0623 216.6631 220.4635
Triglycerides, mg/dL 158.2660 156.466 174.9674 161.1668 141.7662 132.9662
Self-reported ethnicity NA NA NA NA
Caucasian, n (%) 667 (93.8) 2246 (93.7)
African American, n (%) 18 (2.5) 60 (2.5)
Hispanic, n (%) 20 (2.8) 65 (2.7)
Asian, Pacific Islander, other, n (%) 6 (0.8) 27 (1.1)
6 values are standard deviation.
doi:10.1371/journal.pone.0038240.t001
Genes Associated with Event Reduction by Statins
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change in LDL-C from baseline to 3 month visit in the pravastatin
groups of CARE (P.0.4) or PROSPER/PHASE (P.0.09).
We have also investigated the association of SNPs that have
been previously reported to be associated with differential response
to statin therapy. We investigated a variation in HMGCR gene by
combining the analysis of rs17238540 in the case-only studies of
CARE and WOSCOPS, and of a SNP in LD with rs17238540
(rs16872523, r2 = 1) in PROSPER/PHASE. Our analysis indicat-
ed that the major allele of this variant in HMGCR had greater risk
reduction from pravastatin therapy (synergy index= 1.48; 95%CI
0.96 to 2.28; P= 0.076). This finding is consistent with the report
by Chasman et al. (8) and Krauss et al. (5) who found that the
major allele is associated with greater LDL-C reduction by statin
therapy. We have also investigated the rs7412 SNP in APOE. We
had no data for this SNP (or an LD SNP) in the PROSPER/
PHASE study. However, a combined analysis of the case-only
studies of CARE and WOSCOPS found that the major allele of
this SNP (G, allele frequency = 0.95 among CARE Caucasian
cases) is associated with greater risk reduction from pravastatin
therapy (synergy index = 1.49; 955CI 1.01 to 2.22, P = 0.047).
This result is inconsistent with a previous report by Thompson et
Figure 1. Study design. A flow chart outlining the patients and SNPs investigated in the 2 stages of the study.
doi:10.1371/journal.pone.0038240.g001
Figure 2. P-values from a combined case-only analysis of CARE and WOSCOPS. Panel A: A Manhattan plot of the P values from the
combined case-only analysis of CARE and WOSCOPS. The x-axis corresponds to the chromosomal position for 22 chromosomes and the X
chromosome. The Y axis corresponds to the negative base 10 logarithm of the P value. The red line indicates P= 1024 and SNPs above this line are
indicated in blue. Gene symbols are indicated above loci with P,10-5 in the combined analysis of CARE and WOSCOPS. The location of DNAJC5B is
also indicated. Panel B: A quantile-quantile plot of the observed vs. expected P values. The black lines indicate the 95% CI associated with the
expectation that, under the hypothesis of no association, the values will fall on the red diagonal.
doi:10.1371/journal.pone.0038240.g002
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Table 2. Most significant SNPs associated with differential response to pravastatin therapy in a case-only combined analysis of
CARE and WOSCOPS.
SNP CHR Position SI (95%CI) P value A1 A2 A1 Frq. Gene Next closest gene
rs7521242 1 61803889 0.71 (0.59 – 0.84) 8.97E-05 A G 0.45 NFIA TM2D1
rs9436636 1 61812773 1.43 (1.20 – 1.71) 9.09E-05 A G 0.40 NFIA TM2D1
rs2492367 1 231906589 0.54 (0.40 – 0.72) 3.77E-05 A G 0.11 TSNAX-DISC1 DISC1
rs10189905 2 199679110 0.49 (0.36 – 0.67) 1.05E-05 C A 0.10 . SATB2
rs1450092 3 7506105 0.61 (0.48 – 0.77) 4.45E-05 G A 0.18 GRM7 LOC100288428
rs1349282 3 22648091 0.68 (0.57 – 0.82) 3.89E-05 A G 0.42 . UBE2E2
rs1917527 3 65580498 0.69 (0.57 – 0.83) 6.53E-05 A C 0.39 MAGI1 SLC25A26
rs1524962 3 65584681 0.61 (0.50 – 0.75) 3.57E-06 A G 0.26 MAGI1 SLC25A26
rs7629574 3 65587758 0.66 (0.54 – 0.81) 5.05E-05 A C 0.27 MAGI1 SLC25A26
rs7625204 3 102058887 1.54 (1.25 – 1.90) 6.32E-05 A G 0.22 . ZPLD1
rs16861467 3 113752500 0.45 (0.32 – 0.62) 1.65E-06 G A 0.10 KIAA1407 QTRTD1
rs2129571 3 113753571 0.47 (0.34 – 0.65) 3.50E-06 A G 0.10 KIAA1407 QTRTD1
rs9859901 3 113769097 0.46 (0.33 – 0.63) 1.50E-06 A C 0.10 KIAA1407 QTRTD1
rs10155047 3 113772952 0.45 (0.33 – 0.62) 1.13E-06 A G 0.10 KIAA1407 QTRTD1
rs16861476 3 113783883 0.43 (0.31 – 0.60) 6.86E-07 C A 0.10 QTRTD1 KIAA1407
rs13314266 3 113797117 0.45 (0.32 – 0.64) 5.84E-06 G A 0.08 QTRTD1 KIAA1407
rs3732788 3 113804859 0.45 (0.32 – 0.61) 6.93E-07 G A 0.10 QTRTD1 KIAA1407
rs13318232 3 113811688 0.47 (0.35 – 0.65) 3.64E-06 G A 0.10 . QTRTD1
rs4682522 3 113829346 0.52 (0.37 – 0.72) 6.66E-05 C A 0.09 . DRD3
rs13137776 4 11464975 0.66 (0.54 – 0.80) 2.12E-05 G A 0.33 . HS3ST1
rs7671659 4 34353548 1.64 (1.29 – 2.07) 4.53E-05 A G 0.16 . ARAP2
rs9857 5 10680547 0.65 (0.53 – 0.80) 3.84E-05 G A 0.24 DAP ANKRD33B
rs4242084 5 34259360 0.22 (0.11 – 0.45) 3.41E-05 A C 0.03 . C1QTNF3-AMACR
rs4866354 5 34259427 0.22 (0.11 – 0.45) 3.50E-05 G A 0.03 . C1QTNF3-AMACR
rs4626316 5 34278426 0.23 (0.11 – 0.47) 5.03E-05 A G 0.03 . C1QTNF3-AMACR
rs12659030 5 134490348 1.51 (1.24 – 1.85) 6.01E-05 A G 0.25 . LOC340073
rs17076974 5 173619944 1.43 (1.20 – 1.71) 6.68E-05 A G 0.48 . HMP19
rs7705993 5 173620286 1.43 (1.20 – 1.71) 7.09E-05 G A 0.48 . HMP19
rs1544214 6 15990916 1.41 (1.19 – 1.67) 9.29E-05 A G 0.40 . MYLIP
rs7751843 6 22201594 1.91 (1.42 – 2.58) 2.38E-05 A G 0.09 . LINC00340
rs7742508 6 70777350 2.30 (1.58 – 3.35) 1.34E-05 A G 0.05 COL19A1 COL9A1
rs3793048 6 70784746 2.05 (1.47 – 2.85) 2.33E-05 A C 0.08 COL19A1 COL9A1
rs9446187 6 70786466 2.11 (1.51 – 2.96) 1.20E-05 A G 0.08 COL19A1 COL9A1
rs2505039 6 110305904 0.69 (0.58 – 0.83) 6.02E-05 A G 0.45 . GPR6
rs9375683 6 130263591 1.55 (1.26 – 1.91) 3.36E-05 G A 0.21 . L3MBTL3
rs1538185 6 130267753 1.60 (1.28 – 1.99) 3.24E-05 A G 0.20 . L3MBTL3
rs2941528 7 47494959 0.67 (0.54 – 0.82) 9.18E-05 A G 0.26 TNS3 C7orf65
rs1615197 7 105273458 1.45 (1.21 – 1.72) 3.41E-05 G A 0.40 ATXN7L1 EFCAB10
rs12155847 8 58702529 1.48 (1.23 – 1.79) 4.28E-05 G A 0.34 . FAM110B
rs13279522 8 66974252 0.60 (0.48 – 0.77) 4.41E-05 G A 0.17 DNAJC5B TRIM55
rs7863577 9 36539122 0.51 (0.37 – 0.71) 5.37E-05 A C 0.09 . MELK
rs2265346 9 36635409 0.53 (0.39 – 0.72) 6.10E-05 C A 0.10 MELK MIR4475
rs10429616 9 118518733 1.50 (1.26 – 1.80) 7.87E-06 G A 0.44 . LINC00474
rs2418412 9 118541068 1.49 (1.25 – 1.79) 1.14E-05 G A 0.43 . LINC00474
rs2157673 9 118559109 1.55 (1.28 – 1.88) 5.58E-06 G A 0.33 . LINC00474
rs7910196 10 13810059 1.68 (1.31 – 2.14) 3.29E-05 G A 0.15 FRMD4A PRPF18
rs3998860 10 70405855 0.62 (0.50 – 0.78) 4.21E-05 A G 0.19 TET1 CCAR1
rs7913568 10 70410630 0.61 (0.49 – 0.77) 2.71E-05 G A 0.19 TET1 CCAR1
Genes Associated with Event Reduction by Statins
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al. (9) who found that the minor allele of this SNP was associated
with greater LDL-C reduction from atorvastatin therapy.
Discussion
We have conducted a genome-wide association study designed
to identify genetic variants associated with differential CHD event
reduction by pravastatin therapy and found that event reduction
by therapy differed according to genotype for a SNP in the
DNAJC5B gene (P = 4.8610-7). Heterozygotes of rs13279522
(,26% of the population) had 45% event reduction in a combined
analysis of CARE, WOSCOPS and PROSPER/PHASE, while
major homozygotes (,71% of the population) had 13% event
reduction by pravastatin.
DNAJC5B encodes a DnaJ/Hsp40 family member protein
(DNAJ homolog subfamily C member 5B, also known as
CSPbeta). DnaJ/Hsp40 family proteins are co-chaperones char-
acterized by a highly conserved 70 residue J-domain, homologous
to the E.coli DnaJ domain. The J-domain directs the interaction of
DnaJ/Hsp40 proteins with specific Hsp70 family proteins. The
interaction of DnaJ/Hsp40 proteins with Hsp70 proteins activates
the Hsp70 ATPase activity and directs Hsp70 proteins to specific
sub-cellular compartments [16]. CSPbeta is a palmitoylated
membrane protein closely related to CSP, another DnaJ/Hsp40
family protein encoded by DNAJC5 [17,18]. CSP has been
implicated in regulation of vesicular secretion of neurotransmitters
and of insulin secretion in cultured cells [17,19]. The biological
function of CSPbeta is not known; however, the high similarity
[17], (65% identical amino acids, 78% conserved) between CSP
and CSPbeta could suggest a similar biological function.
Thus, DNAJC5B as well as other genes in the same linkage
region (Figure 4), such as TRIM55 and CRH should be further
investigated for potential functional role in modulation of event
reduction by statin therapy.
We found no association between rs13279522 and baseline
LDL-C levels or change in LDL-C levels by pravastatin therapy. If
event reduction by pravastatin is at least partially mediated
through non-LDL-C effects–such as reduction in protein iso-
prenylation and subsequent effect on inflammatory pathway [20],
one could speculate that the rs13279522 variant is involved in
Table 2. Cont.
SNP CHR Position SI (95%CI) P value A1 A2 A1 Frq. Gene Next closest gene
rs10762236 10 70431420 0.61 (0.48 – 0.77) 2.14E-05 C A 0.19 TET1 CCAR1
rs10740308 10 70454896 0.63 (0.50 – 0.79) 6.58E-05 A C 0.19 . TET1
rs7901888 10 70455490 0.63 (0.50 – 0.79) 8.45E-05 A C 0.19 . TET1
rs231358 11 2702513 1.44 (1.21 – 1.72) 4.73E-05 G A 0.51 KCNQ1 KCNQ1DN
rs17347854 11 11247842 0.60 (0.47 – 0.77) 3.73E-05 G A 0.16 . GALNTL4
rs17138705 11 79366322 0.57 (0.43 – 0.74) 3.19E-05 A G 0.14 . ODZ4
rs10831415 11 95466159 1.47 (1.23 – 1.77) 3.08E-05 G A 0.41 . FAM76B
rs1016030 11 95472693 1.45 (1.21 – 1.74) 7.02E-05 G A 0.41 . FAM76B
rs2335451 12 49664786 0.65 (0.54 – 0.80) 3.21E-05 A C 0.28 TUBA1C PRPH
rs10875941 12 49667921 0.66 (0.54 – 0.81) 5.17E-05 G A 0.28 . TUBA1C
rs10778050 12 100768827 1.44 (1.21 – 1.71) 5.19E-05 A G 0.47 SLC17A8 SCYL2
rs2656824 12 127815086 0.67 (0.54 – 0.82) 7.80E-05 A G 0.26 . LOC440117
rs2593270 12 127815178 0.66 (0.54 – 0.80) 3.66E-05 A G 0.26 . LOC440117
rs238272 13 42933855 1.45 (1.21 – 1.74) 7.48E-05 A G 0.31 . AKAP11
rs2273816 13 50294056 1.61 (1.27 – 2.05) 8.71E-05 A G 0.15 KPNA3 EBPL
rs3759607 14 23566143 1.99 (1.42 – 2.79) 7.03E-05 G A 0.07 C14orf119 ACIN1
rs2069542 14 23900794 1.64 (1.28 – 2.11) 8.51E-05 A G 0.15 MYH7 MIR208B
rs2196180 18 44861262 1.48 (1.22 – 1.81) 8.46E-05 A G 0.26 . IER3IP1
rs3861810 18 44864122 1.49 (1.22 – 1.81) 7.69E-05 G A 0.26 . IER3IP1
rs1594887 18 44892369 1.51 (1.24 – 1.84) 4.07E-05 G A 0.26 . IER3IP1
rs2060411 18 44918564 1.50 (1.23 – 1.83) 5.63E-05 A G 0.26 . IER3IP1
rs9807521 18 44935746 1.51 (1.24 – 1.84) 5.17E-05 A C 0.26 . IER3IP1
rs312929 19 3273188 0.68 (0.56 – 0.82) 4.95E-05 G A 0.38 CELF5 NCLN
rs17716275 19 29577230 2.31 (1.52 – 3.53) 9.39E-05 A G 0.05 . LOC100505835
rs2657940 19 52863836 1.55 (1.25 – 1.91) 4.63E-05 A G 0.22 ZNF610 ZNF880
rs2263901 19 52863967 1.55 (1.26 – 1.91) 3.96E-05 G A 0.23 ZNF610 ZNF880
rs6075209 20 17415219 0.69 (0.58 – 0.83) 8.80E-05 A G 0.41 PCSK2 BFSP1
rs2281122 22 35943984 1.61 (1.28 – 2.03) 5.22E-05 A G 0.18 RASD2 MB
rs4830819 X 13044003 0.58 (0.46 – 0.74) 8.23E-06 G A 0.47 . FAM9C
rs2008165 X 13049032 0.59 (0.47 – 0.75) 1.90E-05 G A 0.47 . FAM9C
rs12556591 X 13050626 0.58 (0.46 – 0.74) 1.00E-05 G A 0.47 . FAM9C
doi:10.1371/journal.pone.0038240.t002
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Table 3. Individual and Combined analysis of 54 SNPs in CARE, WOSCOPS, and PROSPER/PHASE.
Combined Analysis CARE WOSCOPS PROSPER
SNP LD SNP r2 SI (95%CI) P value SI (95%CI) P value SI (95%CI) P value SI (95%CI) P value
rs13279522 0.63 (0.52 – 0.75) 4.84E-07 0.63 (0.47 – 0.84) 1.87E-03 0.63 (0.44 – 0.90) 1.12E-02 0.62 (0.46 – 0.84) 2.39E-03
rs3732788 0.61 (0.48 – 0.77) 3.95E-05 0.55 (0.37 – 0.82) 2.80E-03 0.54 (0.33 – 0.87) 1.08E-02 0.72 (0.49 – 1.07) 1.02E-01
rs13318232 0.62 (0.49 – 0.78) 5.66E-05 0.61 (0.42 – 0.89) 1.11E-02 0.49 (0.30 – 0.79) 3.19E-03 0.72 (0.49 – 1.07) 1.03E-01
rs1538185 1.41 (1.19 – 1.67) 6.58E-05 1.61 (1.22 – 2.12) 7.00E-04 1.26 (0.90 – 1.75) 1.77E-01 1.33 (1.01 – 1.75) 4.22E-02
rs16861476 rs3732788 CW, 1 0.62 (0.49 – 0.79) 9.61E-05 0.55 (0.37 – 0.82) 2.80E-03 0.54 (0.33 – 0.87) 1.08E-02 0.77 (0.52 – 1.15) 2.00E-01
rs9859901 0.63 (0.49 – 0.80) 1.17E-04 0.59 (0.40 – 0.87) 6.91E-03 0.50 (0.31 – 0.82) 5.37E-03 0.77 (0.52 – 1.14) 1.90E-01
rs2505039 0.77 (0.67 – 0.88) 1.21E-04 0.69 (0.56 – 0.86) 8.36E-04 0.78 (0.60 – 1.02) 6.83E-02 0.85 (0.68 – 1.06) 1.53E-01
rs10155047 0.62 (0.49 – 0.79) 1.26E-04 0.59 (0.40 – 0.86) 6.05E-03 0.50 (0.31 – 0.80) 4.45E-03 0.77 (0.52 – 1.14) 1.90E-01
rs13314266 0.61 (0.47 – 0.79) 1.45E-04 0.63 (0.41 – 0.94) 2.58E-02 0.46 (0.28 – 0.77) 3.08E-03 0.71 (0.46 – 1.10) 1.25E-01
rs9375683 1.36 (1.16 – 1.60) 1.57E-04 1.54 (1.18 – 2.00) 1.37E-03 1.25 (0.91 – 1.71) 1.76E-01 1.29 (0.99 – 1.68) 6.02E-02
rs16861467 0.60 (0.46 – 0.80) 4.21E-04 0.59 (0.40 – 0.87) 8.43E-03 0.45 (0.27 – 0.73) 1.46E-03 0.76 (0.51 – 1.12) 1.59E-01
rs4682522 0.65 (0.51 – 0.83) 4.47E-04 0.63 (0.42 – 0.93) 2.07E-02 0.56 (0.35 – 0.90) 1.72E-02 0.74 (0.50 – 1.10) 1.42E-01
rs6075209{ 0.77 (0.65 – 0.90) 1.01E-03 0.66 (0.53 – 0.83) 3.42E-04 0.83 (0.61 – 1.12) 2.20E-01 0.84 (0.68 – 1.05) 1.30E-01
rs12659030 1.28 (1.10 – 1.48) 1.19E-03 1.26 (0.99 – 1.62) 6.54E-02 1.42 (1.07 – 1.87) 1.38E-02 1.19 (0.93 – 1.51) 1.63E-01
rs4626316 rs7701604 P, 1 0.45 (0.27 – 0.73) 1.20E-03 0.41 (0.22 – 0.74) 3.13E-03 0.47 (0.17 – 1.31) 1.50E-01 0.73 (0.16 – 3.35) 6.81E-01
rs4242084 rs2148575 CW, 1 0.50 (0.33 – 0.76) 1.31E-03 0.40 (0.21 – 0.75) 4.27E-03 0.47 (0.19 – 1.20) 1.15E-01 0.70 (0.34 – 1.41) 3.16E-01
rs10189905 0.62 (0.45 – 0.84) 2.46E-03 0.50 (0.34 – 0.74) 6.25E-04 0.56 (0.36 – 0.88) 1.21E-02 0.83 (0.56 – 1.21) 3.28E-01
rs17076974 1.29 (1.09 – 1.53) 2.64E-03 1.48 (1.19 – 1.84) 4.37E-04 1.32 (1.02 – 1.71) 3.48E-02 1.12 (0.90 – 1.39) 3.23E-01
rs7705993 1.30 (1.09 – 1.56) 4.13E-03 1.52 (1.22 – 1.88) 1.66E-04 1.30 (1.01 – 1.68) 4.04E-02 1.12 (0.90 – 1.39) 3.13E-01
rs3759607{ 1.57 (1.14 – 2.15) 5.05E-03 2.03 (1.31 – 3.14) 1.46E-03 1.54 (0.89 – 2.67) 1.19E-01 1.21 (0.77 – 1.90) 4.15E-01
rs9436636 1.21 (1.06 – 1.39) 5.45E-03 1.34 (1.07 – 1.67) 1.10E-02 1.26 (0.97 – 1.63) 8.28E-02 1.07 (0.85 – 1.34) 5.61E-01
rs1544214 1.27 (1.07 – 1.50) 6.01E-03 1.41 (1.13 – 1.76) 2.30E-03 1.36 (1.05 – 1.76) 2.05E-02 1.08 (0.87 – 1.35) 4.83E-01
rs2129571 0.66 (0.49 – 0.89) 7.24E-03 0.63 (0.43 – 0.92) 1.65E-02 0.50 (0.30 – 0.81) 5.10E-03 0.87 (0.58 – 1.30) 4.90E-01
rs9857{ 0.80 (0.68 – 0.94) 7.89E-03 0.70 (0.54 – 0.90) 6.34E-03 0.81 (0.58 – 1.14) 2.21E-01 0.91 (0.71 – 1.17) 4.59E-01
rs12155847* 1.31 (1.06 – 1.63) 1.38E-02 1.57 (1.24 – 2.00) 1.71E-04 1.30 (0.95 – 1.79) 1.06E-01 1.11 (0.89 – 1.40) 3.50E-01
rs13137776 0.81 (0.67 – 0.97) 2.32E-02 0.73 (0.58 – 0.93) 9.51E-03 0.74 (0.55 – 0.98) 3.67E-02 0.96 (0.76 – 1.22) 7.58E-01
rs10740308 rs2030057 CW, 0.95 0.73 (0.55 – 0.97) 2.83E-02 0.56 (0.42 – 0.75) 7.97E-05 0.80 (0.57 – 1.12) 2.02E-01 0.88 (0.65 – 1.18) 3.87E-01
rs7901888 rs2030057 CW, 1 0.73 (0.55 – 0.97) 2.83E-02 0.56 (0.42 – 0.75) 7.97E-05 0.80 (0.57 – 1.12) 2.02E-01 0.88 (0.65 – 1.18) 3.87E-01
rs7910196 1.25 (1.02 – 1.53) 3.37E-02 1.32 (0.98 – 1.78) 6.93E-02 1.47 (1.05 – 2.05) 2.63E-02 1.03 (0.75 – 1.40) 8.75E-01
rs231358 rs231355 CW, 0.96 1.20 (1.01 – 1.41) 3.42E-02 1.32 (1.06 – 1.64) 1.27E-02 1.29 (1.00 – 1.66) 5.06E-02 1.02 (0.82 – 1.27) 8.58E-01
rs9446187 1.48 (1.03 – 2.13) 3.45E-02 1.70 (1.17 – 2.46) 5.24E-03 1.92 (1.14 – 3.22) 1.36E-02 1.04 (0.69 – 1.57) 8.48E-01
rs2157673* 1.32 (1.02 – 1.72) 3.73E-02 1.55 (1.21 – 1.98) 4.44E-04 1.47 (1.08 – 2.01) 1.53E-02 1.04 (0.82 – 1.31) 7.42E-01
rs3793048 rs3806005 CW, 1 1.49 (1.02 – 2.18) 3.97E-02 1.76 (1.17 – 2.65) 6.60E-03 1.89 (1.12 – 3.19) 1.65E-02 1.04 (0.69 – 1.57) 8.47E-01
rs10762236 0.73 (0.54 – 0.99) 4.15E-02 0.55 (0.42 – 0.73) 3.02E-05 0.84 (0.60 – 1.17) 2.94E-01 0.87 (0.65 – 1.17) 3.62E-01
rs238272 rs9525613 CW, 1 1.25 (1.01 – 1.56) 4.24E-02 1.35 (1.05 – 1.72) 1.82E-02 1.46 (1.12 – 1.92) 5.59E-03 1.02 (0.81 – 1.29) 8.65E-01
rs7742508 1.55 (1.02 – 2.36) 4.24E-02 1.95 (1.26 – 3.03) 2.83E-03 1.91 (1.09 – 3.35) 2.45E-02 1.05 (0.68 – 1.61) 8.41E-01
rs17716275 1.61 (1.01 – 2.56) 4.53E-02 1.81 (1.07 – 3.07) 2.61E-02 2.19 (1.19 – 4.05) 1.22E-02 0.93 (0.45 – 1.90) 8.32E-01
rs7671659 rs6857038 P, 0.95 1.29 (1.00 – 1.67) 4.89E-02 1.54 (1.17 – 2.02) 1.89E-03 1.38 (0.98 – 1.94) 6.75E-02 1.01 (0.73 – 1.38) 9.76E-01
rs3998860 0.75 (0.56 – 1.00) 5.22E-02 0.57 (0.43 – 0.76) 8.52E-05 0.85 (0.61 – 1.19) 3.44E-01 0.89 (0.67 – 1.19) 4.27E-01
rs1615197* 1.33 (1.00 – 1.77) 5.28E-02 1.29 (1.04 – 1.60) 2.23E-02 1.82 (1.35 – 2.46) 9.69E-05 1.05 (0.84 – 1.31) 6.72E-01
rs7913568 rs3998860 CW, 0.97 0.75 (0.56 – 1.01) 5.75E-02 0.57 (0.43 – 0.76) 8.52E-05 0.85 (0.61 – 1.19) 3.44E-01 0.90 (0.67 – 1.21) 4.85E-01
rs7751843 rs7765440 CW, 1 1.45 (0.98 – 2.14) 6.39E-02 1.80 (1.25 – 2.59) 1.66E-03 1.74 (1.13 – 2.66) 1.11E-02 0.98 (0.67 – 1.44) 9.16E-01
rs1917527{ rs12635482 CW, 0.93 0.86 (0.73 – 1.01) 6.65E-02 0.75 (0.60 – 0.94) 1.08E-02 0.86 (0.65 – 1.14) 2.85E-01 0.98 (0.78 – 1.23) 8.69E-01
rs10831415 rs10831416 CW, 1 1.21 (0.98 – 1.50) 8.08E-02 1.27 (1.02 – 1.57) 3.30E-02 1.45 (1.12 – 1.87) 4.84E-03 0.99 (0.80 – 1.23) 9.29E-01
rs7521242 0.86 (0.71 – 1.03) 9.40E-02 0.72 (0.58 – 0.90) 4.10E-03 0.89 (0.69 – 1.15) 3.91E-01 0.97 (0.78 – 1.21) 8.15E-01
rs1016030 rs10831417 CW, 0.96 1.22 (0.97 – 1.53) 9.66E-02 1.25 (1.01 – 1.56) 4.37E-02 1.49 (1.15 – 1.93) 2.31E-03 0.99 (0.79 – 1.23) 8.93E-01
rs7625204 1.28 (0.95 – 1.71) 1.00E-01 1.57 (1.20 – 2.05) 9.41E-04 1.38 (1.02 – 1.87) 3.67E-02 0.97 (0.75 – 1.26) 8.29E-01
rs9807521{ rs977160 CW, 1 1.20 (0.96 – 1.50) 1.09E-01 1.38 (1.07 – 1.78) 1.32E-02 1.31 (0.95 – 1.81) 9.59E-02 0.98 (0.76 – 1.26) 8.48E-01
rs2281122{ 1.36 (0.92 – 2.00) 1.25E-01 1.32 (0.99 – 1.76) 5.56E-02 2.03 (1.40 – 2.96) 2.14E-04 0.98 (0.75 – 1.28) 8.86E-01
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these pleiotropic pathways. Alternatively, this variant could affect
the susceptibility to high LDL-C levels, and thus be associated with
individuals who benefit more from LDL-C reduction, as has been
previously suggested for another genetic variant [21].
This study has several limitations. The case-only analysis used in
the first stage of this investigation is valid only if genotype and
treatment are independent of each other; however, in a
randomized trial they are independent by design. The minimal
P value observed in this is greater than the commonly used
genome-wide significance threshold of 561028. However, this
observation is sufficiently intriguing to encourage other investiga-
tors to study this SNP in other randomized trials of statin therapy.
This study was powered to detect SNPs associated with a 1.7 fold
differential event reduction by pravastatin therapy, allele frequen-
cy greater than 0.15 at alpha= 1024. Therefore, some SNPs were
likely to be misclassified as non-associated SNPs (false negatives).
Although one of the strengths of this study is that patients were
randomized to 40 mg pravastatin therapy daily in all of the trials
examined, the risk profile of the patients included in these studies
varied. CARE is a secondary prevention trial which recruited
patients who had had a myocardial infarction prior to the
beginning of the study. WOSCOPS is a primary prevention trial
who recruited patients with no history of myocardial infarction,
but who had high risk profile for CHD. The PROSPER/PHASE
study recruited patients who were elderly, either with or without
history of CHD. Other potential differences between the studies,
such as concomitant medication use and environmental exposures
have not been accounted for. However, the randomized nature of
these studies goes a long way toward addressing these potential
biases.
In conclusion, in this genome wide association analysis of event
reduction by pravastatin therapy, we have identified a SNP in the
DNAJC5B gene that was associated with differential event
reduction by pravastatin therapy in CARE, WOSCOPS, and
PROSPER. Widespread replication of this association in multiple
additional studies and potentially a clinical trial demonstrating
improved outcomes or an investigation supporting the biological
rationale for the mechanism of action of this variant are needed
before the testing of this variant is introduced into clinical practice.
Materials and Methods
Study Design
This investigation was designed to identify genetic polymor-
phisms that were associated with differential CHD event reduction
by pravastatin therapy. The individuals in the study were drawn
from three randomized, placebo-controlled trials of pravastatin:
CARE, WOSCOPS, and PROSPER/PHASE. We conducted the
Table 3. Cont.
Combined Analysis CARE WOSCOPS PROSPER
SNP LD SNP r2 SI (95%CI) P value SI (95%CI) P value SI (95%CI) P value SI (95%CI) P value
rs1524962{ 0.81 (0.61 – 1.07) 1.30E-01 0.65 (0.50 – 0.84) 1.07E-03 0.78 (0.56 – 1.08) 1.28E-01 1.02 (0.80 – 1.29) 8.85E-01
rs1450092 0.80 (0.60 – 1.07) 1.35E-01 0.62 (0.46 – 0.84) 2.05E-03 0.79 (0.57 – 1.11) 1.74E-01 1.02 (0.77 – 1.35) 8.84E-01
rs2335451{ rs10875941 CWP,1 0.77 (0.54 – 1.10) 1.50E-01 0.78 (0.62 – 0.99) 4.51E-02 0.52 (0.36 – 0.75) 3.99E-04 1.05 (0.82 – 1.34) 7.13E-01
rs10875941{ 0.76 (0.52 – 1.11) 1.50E-01 0.78 (0.62 – 0.99) 4.51E-02 0.50 (0.34 – 0.71) 1.66E-04 1.05 (0.82 – 1.34) 7.13E-01
rs2593270 rs4765531 CW, 1 0.79 (0.58 – 1.09) 1.57E-01 0.71 (0.55 – 0.92) 9.77E-03 0.64 (0.47 – 0.86) 2.93E-03 1.07 (0.85 – 1.36) 5.56E-01
rs2656824 rs4765531 CW, 1 0.79 (0.58 – 1.09) 1.57E-01 0.71 (0.55 – 0.92) 9.77E-03 0.64 (0.47 – 0.86) 2.93E-03 1.07 (0.85 – 1.36) 5.56E-01
rs2941528* 0.78 (0.56 – 1.10) 1.59E-01 0.75 (0.58 – 0.97) 2.68E-02 0.58 (0.41 – 0.81) 1.38E-03 1.07 (0.83 – 1.38) 6.04E-01
rs2196180 rs1560901 CW, 1 1.16 (0.93 – 1.45) 1.78E-01 1.37 (1.07 – 1.76) 1.33E-02 1.23 (0.92 – 1.63) 1.58E-01 0.95 (0.75 – 1.21) 6.87E-01
rs3861810 rs1560901 CW, 1 1.16 (0.93 – 1.46) 1.83E-01 1.37 (1.07 – 1.76) 1.33E-02 1.23 (0.92 – 1.63) 1.58E-01 0.95 (0.75 – 1.21) 6.73E-01
rs2273816* 1.32 (0.87 – 2.01) 1.87E-01 1.59 (1.16 – 2.18) 4.20E-03 1.69 (1.16 – 2.47) 6.17E-03 0.88 (0.65 – 1.20) 4.30E-01
rs1594887 rs1529806 CW, 1 1.16 (0.92 – 1.46) 1.97E-01 1.39 (1.09 – 1.79) 9.01E-03 1.20 (0.91 – 1.59) 2.03E-01 0.95 (0.75 – 1.21) 6.70E-01
rs2060411 1.15 (0.92 – 1.44) 2.27E-01 1.33 (1.04 – 1.70) 2.48E-02 1.25 (0.94 – 1.66) 1.22E-01 0.93 (0.73 – 1.18) 5.45E-01
rs7629574{ 0.84 (0.62 – 1.13) 2.41E-01 0.66 (0.51 – 0.84) 1.02E-03 0.84 (0.61 – 1.15) 2.73E-01 1.06 (0.83 – 1.35) 6.22E-01
rs10429616 1.20 (0.88 – 1.63) 2.41E-01 1.50 (1.21 – 1.87) 2.56E-04 1.27 (0.97 – 1.65) 7.95E-02 0.91 (0.73 – 1.13) 4.07E-01
rs10778050{ rs4764738 CW, 0.93 1.20 (0.88 – 1.63) 2.45E-01 1.12 (0.90 – 1.39) 3.09E-01 1.70 (1.26 – 2.28) 4.58E-04 0.95 (0.76 – 1.18) 6.41E-01
rs17138705{ 0.76 (0.47 – 1.22) 2.51E-01 0.54 (0.39 – 0.75) 2.70E-04 0.70 (0.44 – 1.11) 1.28E-01 1.13 (0.83 – 1.53) 4.51E-01
rs2492367 0.71 (0.39 – 1.29) 2.62E-01 0.42 (0.28 – 0.61) 5.61E-06 0.76 (0.51 – 1.13) 1.76E-01 1.13 (0.82 – 1.57) 4.56E-01
rs1349282 0.82 (0.58 – 1.16) 2.62E-01 0.82 (0.66 – 1.02) 8.15E-02 0.59 (0.46 – 0.77) 7.47E-05 1.12 (0.88 – 1.43) 3.45E-01
rs2418412 1.19 (0.87 – 1.64) 2.77E-01 1.52 (1.22 – 1.89) 1.91E-04 1.25 (0.96 – 1.62) 1.02E-01 0.90 (0.72 – 1.12) 3.43E-01
rs7863577 0.83 (0.59 – 1.18) 3.12E-01 0.64 (0.44 – 0.93) 1.82E-02 0.82 (0.50 – 1.34) 4.29E-01 1.13 (0.75 – 1.71) 5.47E-01
rs2657940 1.18 (0.85 – 1.64) 3.19E-01 1.46 (1.13 – 1.89) 4.21E-03 1.32 (0.97 – 1.80) 7.41E-02 0.86 (0.66 – 1.13) 2.70E-01
rs2265346 rs10973012 P, 1 0.84 (0.60 – 1.19) 3.24E-01 0.67 (0.46 – 0.96) 2.93E-02 0.77 (0.48 – 1.22) 2.66E-01 1.15 (0.79 – 1.68) 4.57E-01
rs2263901 rs2657940 1 1.17 (0.85 – 1.63) 3.32E-01 1.45 (1.13 – 1.88) 4.17E-03 1.30 (0.96 – 1.77) 9.54E-02 0.86 (0.66 – 1.13) 2.70E-01
rs17347854 0.80 (0.51 – 1.27) 3.44E-01 0.69 (0.51 – 0.93) 1.44E-02 0.58 (0.41 – 0.84) 3.88E-03 1.26 (0.92 – 1.72) 1.44E-01
rs312929 0.88 (0.64 – 1.21) 4.44E-01 0.72 (0.58 – 0.91) 5.06E-03 0.79 (0.60 – 1.03) 8.21E-02 1.23 (0.94 – 1.61) 1.36E-01
*case-only data in CARE and WOSCOPS.
{case-only data in WOSCOPS.
doi:10.1371/journal.pone.0038240.t003
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investigation in two stages (Figure 1). In the first stage, we
identified genetic polymorphisms that were associated with
differential event reduction by pravastatin therapy by conducting
a GWAS among individuals who had CHD event during the
CARE and WOSCOPS trials. In the second stage, polymorphisms
that were nominally associated with differential event reduction
Figure 4. Genomic region of rs13279522. A ,500 kb region centered around rs13279522 is from UCSC browser (http://genome.ucsc.edu).
Linkage Disequilibrium (LD) information is color-coded at the bottom, genes (horizontal blue lines) and exons (vertical blue lines) are indicated above
the LD representation. Vertical orange line correspond to the negative base 10 logarithm of the P value from a case only analysis of CARE and
WOSCOPS for SNPs in this region. The location of rs13279522 is indicated by a black arrow.
doi:10.1371/journal.pone.0038240.g004
Figure 3. Risk reduction according to genotype for rs13279522. Risk estimate and 95% confidence intervals are indicated for each genotype
group in each study, as well as for the combined analysis of the studies. The number of individuals in each group is indicated.
doi:10.1371/journal.pone.0038240.g003
Genes Associated with Event Reduction by Statins
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e38240
(P,0.0001) were investigated in PROSPER/PHASE, and in an
expanded analysis of CARE and WOSCOPS that added the
included non-cases from these studies.
Study Population
The population for this investigation was derived from three
randomized, placebo-controlled trials of pravastatin: CARE,
WOSCOPS, and PROSPER/PHASE. All patients in this
investigation provided a written informed consent and the study
protocol was approved by the institutional ethics review boards.
CARE has been described previously [22]. Briefly, CARE was a
secondary prevention double-blind trial of 4159 patients who had
had a myocardial infarction between 3 and 20 months before
randomization and had plasma total cholesterol levels below
240 mg/dL (3583 men and 576 women). These patients were
randomly assigned to 40 mg of pravastatin per day or placebo. All
laboratory measurements were made in a core laboratory. DNA in
sufficient quantity and quality for this genetic investigation was
available from 3109 CARE patients. In the first stage of this
investigation, the CARE study population consisted of 682
patients who had a CHD event (a composite endpoint of fatal
coronary event, nonfatal MI, or revascularization procedure) and
whose whole genome scan data passed quality control. The second
stage of this investigation included all CARE patients (those with
and those without CHD events) who provided adequate DNA.
WOSCOPS has been previously described [23]. Briefly,
WOSCOPS was a primary prevention double-blind trial of 6595
men, 45 to 64 years of age with no history of myocardial infarction
and with mean plasma total cholesterol level of 272 mg/dL who
were randomly assigned to 40 mg of pravastatin per day or
placebo. All laboratory measurements were made in a core
laboratory. DNA in sufficient quantity and quality for this genetic
investigation was available from 5431 WOSCOPS patients. In the
first stage of this investigation, the WOSCOPS study population
consisted of 383 of these patients who had a CHD event (a
composite endpoint of death from coronary heart disease, nonfatal
MI, or revascularization procedures) and whose whole-genome
scan data passed quality control. The second stage of this
investigation included all WOSCOPS patients (those with and
those without CHD events) who provided adequate DNA.
PROSPER has been previously described [24]. Briefly,
PROSPER was a randomized, double-blind, placebo controlled
trial of 5804 patients (2804 men, 3000 women) aged at least 70
years at enrollment with baseline total cholesterol levels that
ranged from 155 mg/dL to 348 mg/dL. The trial included both
patients with pre-existing vascular disease and those who were at
risk for cardiovascular events due to smoking, hypertension, or
diabetes. Patients were randomized to treatment with 40 mg
pravastatin per day or placebo. All laboratory measurements were
made in a core laboratory. DNA in sufficient quantity and quality
for this genetic investigation was available from 5244 PROSPER
patients who were genotyped in the genome-wide association
analysis in the PROSPER/PHASE study. The primary endpoint
was the composite endpoint of death from coronary heart disease,
nonfatal MI, and occurrence of clinical stroke, either fatal or non-
fatal.
Genotyping
Genotyping for the whole-genome scan of the first stage was
conducted using Infinium HumanOMNI-1 Quad V1 Beadchip
from Illumina (San Diego CA) which interrogates 1.14 million
markers. Quality control was performed according to Fellay et al.
[22]. Briefly, we excluded 4 samples (1 from CARE and 3 from
WOSCOPS) that had,99% call rate. The call rate was calculated
after exclusion of: intensity-only markers (127,119), markers that
did not achieve .99% call frequency (11,355), markers that had
poor clustering (1,035) [25], Y chromosome markers that had
.0% frequency in females (145), and X chromosome markers that
had .1% heterozygote frequency in males (944). Genotyping
reproducibility for 23 samples that were run in duplicates was
.99.99%. In the second stage of this investigation, genotyping in
CARE and WOSCOPS was performed by allele-specific PCR as
previously described [26], the genotype concordance for samples
that were genotyped by both methods was .99.8%. The
genotyping data for the PROSPER/PHASE study was extracted
from Illumina 660-Quad beadchips following manufacturer’s
instructions. These beadchips contain 657,366 single nucleotide
polymorphism (SNP) and copy number variants.
Statistical Analysis
In order to make efficient use of the available resources for
genotyping, in the first stage of this investigation, a case-only
design was used to estimate whether event reduction during
pravastatin therapy differed according to genotype. Since the
genotype and treatment are independent of each other in a
randomized clinical trial, the genotype frequencies among treated
and untreated cases can be used to estimate the interaction
between pravastatin treatment and genotype and to calculate the
corresponding P value.
The P value for each SNP in the first stage of this investigation
was evaluated in a logistic regression model with treatment status
as the dependent variable and SNP coded in an additive model as
the predictor variable. The rationale for this design is that if one of
the alleles is associated with better event reduction by pravastatin
treatment compared with placebo, we would expect that this allele
frequency would be lower among cases of the treatment group
compared with the placebo group. This expectation is justified if
drug allocation is independent of genotype, a valid assumption by
design in a randomized study. The odds ratio for the SNP from
this logistic regression model was referred to as the synergy index
by Davis et al. [15]. The regression model also included the
following covariates: age for WOSCOPS and age, sex, and self
reported ethnicity for CARE. The logistic regression models were
fitted separately for CARE and WOSCOPS and the evidence for
interaction from CARE and WOSCOPS was combined in a fixed
effects model. The logistic regression and combined analyses of
CARE and WOSCOPS were performed using PLINK version
1.07 [27].
In the second stage of this investigation, a time to event analysis
was performed using Cox proportional hazards models and the
Wald test was used to assess the effect of pravastatin, compared
with placebo, on coronary events. Interaction between SNP and
pravastatin treatment was assessed from models that included an
interaction term between SNP and pravastatin therapy and
included the following covariates: age for WOSCOPS, age, sex,
and country of clinical center for PROSPER/PHASE, and age,
sex, and principal components of the genetic variability using
genotypes of 746 SNPs as previously described [28] for CARE.
We used principal component analysis to exclude outliers (likely
non-Caucasians) from the analysis of PROSPER/PHASE. Out-
liers were defined as those with a component value greater than 4
standard deviation away from the component value determined in
the HapMap CEU population. R statistical software [29] was used
for Cox regression models and for analyses that combined CARE,
WOSCOPS, and PROSPER/PHASE studies.
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